Xenios Ag

xenios ag intends to fundamentally change the future of extracorporeal therapies for heart and lung failure novalung gmbh and medos ag jointly establish xenios ag as a common holding company to create synergies in administration, research and development, regulatory affairs and quality management. xenios ag strives to become market and technology leader in extracorporeal therapies and will address new global markets and business areas.the inception of xenios ag marks a milestone in the long and successful collaboration of novalung gmbh and medos ag. xenios ag, which was recently founded by the two medical device companies, is focused on developing and manufacturing innovative devices for minimally invasive lung and heart support. at xenios ag approximately 220 team members design, manufacture, and market groundbreaking solutions for lung failure as well as surgical and interventional solutions for the treatment of heart disease.